Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 3, 2003, Pages 170-177

  Skinner, Michael H ^a   Kuan, Han Yi ^b   Pan, Alan ^b   Sathirakul, Korbtham ^b   Knadler, Mary Pat ^b   Gonzales, Celedon R ^b   Yeo, Kwee Poo ^b   Reddy, Shobha ^b   Lim, Maggie ^b   Ayan Oshodi, Mosun ^b   Wise, Stephen D ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DESIPRAMINE; DULOXETINE; PAROXETINE;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALAISE; MALE; NAUSEA; NERVOUSNESS; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DESIPRAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; REFERENCE VALUES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 0037374043     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.28     Document Type: Article

References (19)

1. Pitsikas N. Duloxetine Eli Lilly & Co. Curr Opin Invest Drugs 2000;1:116-21.
2. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995;274:1014-24.
3. Danuser H, Bemis K, Thor KB. Pharmacological analysis of the noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat. J Pharmacol Exp Ther 1995;274:820-5.
4. 2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996;118:150-4.
5. Rueter LE, Kasamo K, de Montigny C, Blier P. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1998;357:600-10.
6. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231.
7. Bergstrom RF, Peyton AL, Lemberger L. Quantitation and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
8. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
9. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
10. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29 Suppl 1:10-19.
11. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988;35:167-71.
12. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B 1996;678:113-28.
13. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit 1998;20:517-24.
14. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3:197-204.
15. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
16. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999;19:155-63.
17. Norpramin. In: Physicians' desk reference. 55th ed. Montvale (NJ): Medical Economics; 2001. p. 722-4.
18. Food and Drug Administration (US), Center for Drug Evaluation and Research. Guidance: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. Rockville (MD): Office of Training and Communications, Division of Drug Information HFD-210; 1999 Nov.
19. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effect on oxidative drug metabolism. Clin Pharmacokinet 1997;32 Suppl 1:1-21.